[{"address1": "100 Overlook Center", "address2": "Suite 102", "city": "Princeton", "state": "NJ", "zip": "08540", "country": "United States", "phone": "609 375 2227", "website": "https://www.sonnetbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pankaj  Mohan Ph.D.", "age": 58, "title": "Founder, Chairman, CEO & President", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 538998, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John K. Cini Ph.D.", "age": 70, "title": "Chief Scientific Officer & Co-Founder", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 397750, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jay  Cross", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 389953, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 4.51, "open": 4.6, "dayLow": 4.3, "dayHigh": 4.6, "regularMarketPreviousClose": 4.51, "regularMarketOpen": 4.6, "regularMarketDayLow": 4.3, "regularMarketDayHigh": 4.6, "beta": 1.004, "forwardPE": -0.30548128, "volume": 15704, "regularMarketVolume": 15704, "averageVolume": 30732, "averageVolume10days": 46690, "averageDailyVolume10Day": 46690, "marketCap": 2971930, "fiftyTwoWeekLow": 4.14, "fiftyTwoWeekHigh": 18.72, "priceToSalesTrailing12Months": 53.183193, "fiftyDayAverage": 6.0448, "twoHundredDayAverage": 10.4304, "currency": "USD", "enterpriseValue": -432214, "floatShares": 558313, "sharesOutstanding": 650313, "sharesShort": 20844, "sharesShortPriorMonth": 4342, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0321, "heldPercentInsiders": 0.054390002, "heldPercentInstitutions": 0.13969, "shortRatio": 0.68, "shortPercentOfFloat": 0.0326, "bookValue": 4.014, "priceToBook": 1.1385152, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -7985378, "trailingEps": -0.96, "forwardEps": -14.96, "lastSplitFactor": "1:26", "lastSplitDate": 1585785600, "enterpriseToRevenue": -7.735, "enterpriseToEbitda": 0.035, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SONN", "underlyingSymbol": "SONN", "shortName": "Sonnet BioTherapeutics Holdings", "longName": "Sonnet BioTherapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1162305000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e0f4f091-b896-3bb3-bb50-c62febf22cab", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.57, "targetHighPrice": 240.0, "targetLowPrice": 56.0, "targetMeanPrice": 148.0, "targetMedianPrice": 148.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 3554331, "totalCashPerShare": 5.466, "ebitda": -12263398, "totalDebt": 150186, "quickRatio": 1.31, "currentRatio": 1.649, "totalRevenue": 55881, "debtToEquity": 5.736, "revenuePerShare": 0.118, "returnOnAssets": -0.96928, "returnOnEquity": -2.64567, "freeCashflow": -9881685, "operatingCashflow": -9996666, "operatingMargins": -219.68546, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]